Literature DB >> 34272718

Case Study 11: Considerations for Enzyme Mapping Experiments-Interaction Between the Aldehyde Oxidase Inhibitor Hydralazine and Glutathione.

Rachel D Crouch1, Jessica L Beers2, Klarissa D Jackson3.   

Abstract

Often it may be convenient and efficient to address multiple research questions with a single experiment. In many instances, however, the best approach is to design the experiment to address one question at a time. The design of enzyme mapping experiments is discussed in this chapter, focusing on considerations pertinent to the study of aldehyde oxidase (AO) vs. cytochrome P450 metabolism. Specifically, a case is presented in which reduced glutathione (GSH) was included in an experiment with human liver S9 fraction to trap reactive metabolites generated from cytochrome P450-mediated metabolism of lapatinib and its O-dealkylated metabolite, M1 (question 1). The AO inhibitor hydralazine was included in this experiment to investigate the involvement of AO-mediated metabolism of M1 (question 2). The presence of GSH was found to interfere with the inhibitory activity of hydralazine. Consideration of the time-dependent nature of hydralazine inhibitory activity toward AO when designing this experiment could have predicted the potential for GSH to interfere with hydralazine. This case underscores the importance of clearly identifying the research question, tailoring the experimental protocol to answer that question, and then meticulously considering how the experimental conditions could influence the results, particularly if attempting to address multiple questions with a single experiment.
© 2021. Springer Science+Business Media, LLC, part of Springer Nature.

Entities:  

Keywords:  Aldehyde oxidase; Cytochrome P450; Enzyme mapping; Glutathione trapping; Hydralazine; Metabolic activation; Time-dependent inhibition

Mesh:

Substances:

Year:  2021        PMID: 34272718      PMCID: PMC9147050          DOI: 10.1007/978-1-0716-1554-6_30

Source DB:  PubMed          Journal:  Methods Mol Biol        ISSN: 1064-3745


  26 in total

1.  Aldehyde oxidase: an enzyme of emerging importance in drug discovery.

Authors:  David C Pryde; Deepak Dalvie; Qiyue Hu; Peter Jones; R Scott Obach; Thien-Duc Tran
Journal:  J Med Chem       Date:  2010-09-20       Impact factor: 7.446

Review 2.  A comprehensive listing of bioactivation pathways of organic functional groups.

Authors:  Amit S Kalgutkar; Iain Gardner; R Scott Obach; Christopher L Shaffer; Ernesto Callegari; Kirk R Henne; Abdul E Mutlib; Deepak K Dalvie; Jae S Lee; Yasuhiro Nakai; John P O'Donnell; Jason Boer; Shawn P Harriman
Journal:  Curr Drug Metab       Date:  2005-06       Impact factor: 3.731

3.  Mechanism-based inactivation of cytochrome P450 3A4 by lapatinib.

Authors:  Woon Chien Teng; Jing Wen Oh; Lee Sun New; Michelle D Wahlin; Sidney D Nelson; Han Kiat Ho; Eric Chun Yong Chan
Journal:  Mol Pharmacol       Date:  2010-07-12       Impact factor: 4.436

Review 4.  Regulation of hepatic glutathione metabolism and its role in hepatotoxicity.

Authors:  M Kretzschmar
Journal:  Exp Toxicol Pathol       Date:  1996-07

5.  Human metabolism of lapatinib, a dual kinase inhibitor: implications for hepatotoxicity.

Authors:  Stephen Castellino; Michael O'Mara; Kevin Koch; David J Borts; Gary D Bowers; Christopher MacLauchlin
Journal:  Drug Metab Dispos       Date:  2011-09-30       Impact factor: 3.922

6.  Evidence for substrate-dependent inhibition profiles for human liver aldehyde oxidase.

Authors:  John T Barr; Jeffrey P Jones
Journal:  Drug Metab Dispos       Date:  2012-09-20       Impact factor: 3.922

Review 7.  The role of metabolic activation in drug-induced hepatotoxicity.

Authors:  B Kevin Park; Neil R Kitteringham; James L Maggs; Munir Pirmohamed; Dominic P Williams
Journal:  Annu Rev Pharmacol Toxicol       Date:  2005       Impact factor: 13.820

8.  Hydralazine as a selective probe inactivator of aldehyde oxidase in human hepatocytes: estimation of the contribution of aldehyde oxidase to metabolic clearance.

Authors:  Timothy J Strelevitz; Christine C Orozco; R Scott Obach
Journal:  Drug Metab Dispos       Date:  2012-04-20       Impact factor: 3.922

Review 9.  Drug-protein adducts: an industry perspective on minimizing the potential for drug bioactivation in drug discovery and development.

Authors:  David C Evans; Alan P Watt; Deborah A Nicoll-Griffith; Thomas A Baillie
Journal:  Chem Res Toxicol       Date:  2004-01       Impact factor: 3.739

10.  Efficiency in Drug Discovery: Liver S9 Fraction Assay As a Screen for Metabolic Stability.

Authors:  Samantha J Richardson; April Bai; Ashutosh A Kulkarni; Mehran F Moghaddam
Journal:  Drug Metab Lett       Date:  2016
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.